Navigation Links
Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
Date:7/12/2012

Company will secure the additional capital necessary to fund its operations beyond August 2012 on acceptable terms, if at all.  Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

PBI filed a registration statement (including a prospectus) with the SEC for an offering to which this communication may relate. Before you invest, you should read the prospectus in that registration statement for the offering and other documents PBI has filed with the SEC for more complete information about PBI and the offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, PBI can arrange to send you the prospectus, when available, upon request.

For more information about PBI and this press release, please click on the following link:
http://www.pressurebiosciences.com

Investor Contacts:


Richard T. Schumacher, President & CEO

Pressure BioSciences, Inc.

Nate Lawrence, Vice President of Sales & Marketing

(508) 230-1828 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
2. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
3. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
4. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
5. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
6. UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt
7. AMPAC Fine Chemicals Continues to Invest in Quality Systems
8. Profil Institute Continues to Publish New Findings in Metabolic Research
9. BiOptix continues support of Colorado-based research institutions
10. China Cord Blood Corporation Continues Share Repurchase Program
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015 Dr. Robert Hanzlik, ... chemical toxicity carries implications for advancing the creation of ... at National University , the second-largest private, nonprofit ... Dr. Hanzlik, a professor at the University of Kansas ... drug design, starts at 5 p.m. and takes place ...
(Date:4/27/2015)... 27, 2015 Deadly viruses such as ... resident of the University City Science Center's ... , With a $4.5 million Phase 2 SBIR ... Phelix Therapeutics is focused on therapies for ... The company is developing first-in-class protease inhibitors based on ...
(Date:4/27/2015)... -- Editor Note: For more ... . Investor-Edge has initiated coverage on ... LXRX ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ... Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ), and ... report on Lexicon Pharma can be accessed at ...
(Date:4/27/2015)... 2015 SynGen Inc., a company that focuses ... harvest stem and progenitor cells from umbilical cord blood, ... that it has added three new members to its ... Business Units focus on product commercialization. ... Vice President and Chief Financial Officer.  Chuck was most ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5SynGen Inc. Expands Its Management Team 2
... BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer ... for cells and tissues, today announced that it ... cryopreservation media for umbilical cord blood stem cells, ... market. BioLife Solutions, which will be exhibiting at ...
... University say they have discovered a simple method for ... nanostructure that some believe could replace silicon as the ... intense scientific research in recent years, graphene is a ... atoms arranged in a hexagonal lattice. It is the ...
... Drs. Samuel and Elenore Bogoch of BioRadar UK Ltd. announced ... of the EHEC lethal strains of E. Coli preceded the ... have been studied in laboratories in Germany and elsewhere since ... databases. Replikins are subsequences of the genome of an infectious ...
Cached Biology Technology:BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells 2BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells 3Northern Illinois University scientists find simple way to produce graphene 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... learning more about how protein gets in the urine when ... blocks it. "We have known for a long time ... in diabetes," said Dr. David Pollock, renal physiologist at the ... that a new class of drugs called endothelin A receptor ...
... days of critical international discussion and debate, led by ... Clinical Densitometry (ISCD) and the International Osteoporosis Foundation (IOF), ... pertaining to the interpretation and use of FRAX in ... Tool (FRAX), with models for some 26 countries, is ...
... that applying a stem cell-infused patch together with overexpression ... to damaged cardiac tissue following heart attack and resulted ... also found that function improved more so than when ... that is being studied elsewhere. These findings are ...
Cached Biology News:Scientists learn more about how kidneys fail and how new drugs may intervene 2International discussions on FRAX smooth the way for implementation in clinical practice 2Stem cell patch may result in improved function following heart attack 2Stem cell patch may result in improved function following heart attack 3
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
Biology Products: